Correlation of [18F]-2-fluoro-deoxy-D-glucose positron emission tomography standard uptake values with the cellular composition of stage I nonsmall cell lung cancer

Cancer

Volumn 116, Issue 17, 2010, Pages 4095-4102

  Christensen, Jared D ^a   Colby, Tom V ^b   Patz Jr , Edward F ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Diagnostic imaging; Neoplasm staging; Nonsmall cell lung carcinoma; Pathology; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE;

ADULT; AGED; ARTICLE; CANCER STAGING; CELL COMPOSITION; CELL TYPE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION COEFFICIENT; DRUG TUMOR LEVEL; FEMALE; FIBROSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATORY CELL; INFORMED CONSENT; INSTITUTIONAL REVIEW; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MALE; NECROSIS; OUTCOME ASSESSMENT; PATHOLOGIST; POSITRON EMISSION TOMOGRAPHY; PRIMARY TUMOR; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; STROMA; TISSUE SECTION; TUMOR CELL; TUMOR DIFFERENTIATION; CELL STRUCTURE; INFLAMMATION; LUNG TUMOR; METABOLISM; MIDDLE AGED; NON SMALL CELL LUNG CANCER; PATHOLOGY; PROCEDURES; SCINTISCANNING; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CELLULAR STRUCTURES; FEMALE; FIBROSIS; FLUORODEOXYGLUCOSE F18; GLUCOSE; HUMANS; INFLAMMATION; LUNG NEOPLASMS; MALE; MIDDLE AGED; NECROSIS; POSITRON-EMISSION TOMOGRAPHY;

EID: 77956807447     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25302     Document Type: Article

References (38)

1. Ahuja V, Coleman RE, Herndon J, Patz EF. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma. Cancer. 1998;83:918-924.
2. Dhital K, Saunders CA, Seed PT, O'Doherty MJ, Dussek J. [(18)F]Fluorodeoxyglucose positron emission tomography and its prognostic value in lung cancer. Eur J Cardiothorac Surg. 2000;18:425-428.
3. Downey RJ, Akhurst T, Gonen M, et al. Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol. 2004;22:3255-3260.
4. Cerfolio RJ, Bryant AS, Ohja B, Bartolucci AA. The maximum standardized uptake values on positron emission tomography of a nonsmall cell lung cancer predict stage, recurrence, and survival. J Thorac Cardiovasc Surg. 2005;130:151-159.
5. Duhaylongsod FG, Lowe VJ, Patz EF, Vaughn AL, Coleman RE, Wolfe WG. Lung tumor growth correlates with glucose metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography. Ann Thorac Surg. 1995;60:1348-1352.
6. Duhaylongsod FG, Lowe VJ, Patz EF, Vaughn AL, Coleman RE, Wolfe WG. Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET). J Thorac Cardiovasc Surg. 1995;110:130-139; discussion 139-140.
7. Hellwig D, Gröschel A, Graeter TP, et al. Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated nonsmall cell lung cancer. Eur J Nucl Med Mol Imaging. 2006;33:13-21.
8. Higashi K, Ueda Y, Arisaka Y, et al. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected nonsmall cell lung cancer. J Nucl Med. 2002;43:39-45.
9. Jeong HJ, Min JJ, Park JM, et al. Determination of the prognostic value of [(18)F]fluorodeoxyglucose uptake by using positron emission tomography in patients with nonsmall cell lung cancer. Nucl Med Commun. 2002;23:865-870.
10. Marom EM, McAdams HP, Erasmus JJ, et al. Staging non-small cell lung cancer with whole-body PET. Radiology. 1999;212:803-809.
11. Patz EF, Connolly J, Herndon J. Prognostic value of thoracic FDG PET imaging after treatment for nonsmall cell lung cancer. AJR Am J Roentgenol. 2000;174:769-774.
12. Sasaki R, Komaki R, Macapinlac H, et al. [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of nonsmall-cell lung cancer. J Clin Oncol. 2005;23:1136-1143.
13. Vansteenkiste JF, Stroobants SG, Dupont PJ, et al. Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in nonsmall-cell lung cancer: an analysis of 125 cases. Leuven Lung Cancer Group. J Clin Oncol. 1999;17:3201-3206.
14. Vesselle H, Freeman JD, Wiens L, et al. Fluorodeoxyglucose uptake of primary nonsmall cell lung cancer at positron emission tomography: new contrary data on prognostic role. Clin Cancer Res. 2007;13:3255-3263.
15. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
16. Gail MH, Eagan RT, Feld R, et al. Prognostic factors in patients with resected stage I nonsmall cell lung cancer. A report from the Lung Cancer Study Group. Cancer. 1984;54:1802-1813.
17. Graziano SL. nonsmall cell lung cancer: clinical value of new biological predictors. Lung Cancer. 1997;17(suppl 1):S37-S58.
18. Harpole DH, Herndon JE, Young WG, Wolfe WG, Sabiston DC. Stage I nonsmall cell lung cancer. A multivariate analysis of treatment methods and patterns of recurrence. Cancer. 1995;76:787-796.
19. Ichinose Y, Hara N, Ohta M, et al. Is T factor of the TNM staging system a predominant prognostic factor in pathologic stage I nonsmall-cell lung cancer? A multivariate prognostic factor analysis of 151 patients. J Thorac Cardiovasc Surg. 1993;106:90-94.
20. Johnson BE. Biologic and molecular prognostic factors - impact on treatment of patients with nonsmall cell lung cancer. Chest. 1995;107:287S-290S.
21. Lipford EH, Eggleston JC, Lillemoe KD, Sears DL, Moore GW, Baker RR. Prognostic factors in surgically resected limited-stage, nonsmall cell carcinoma of the lung. Am J Surg Pathol. 1984;8:357-365.
22. Naruke T, Goya T, Tsuchiya R, Suemasu K. Prognosis and survival in resected lung carcinoma based on the new international staging system. J Thorac Cardiovasc Surg. 1988;96:440-447.
23. Fischer B, Lassen U, Mortensen J, et al. Preoperative staging of lung cancer with combined PET-CT. N Engl J Med. 2009;361:32-39.
24. Dooms C, van Baardwijk A, Verbeken E, et al. Association between 18F-fluoro-2-deoxy-D-glucose uptake values and tumor vitality: prognostic value of positron emission tomography in early-stage nonsmall cell lung cancer. J Thorac Oncol. 2009;4:822-828.
25. de Geus-Oei LF, van der Heijden HF, Corstens FH, Oyen WJ. Predictive and prognostic value of FDG-PET in non-small-cell lung cancer: a systematic review. Cancer. 2007;110:1654-1664.
26. Hoang JK, Hoagland LF, Coleman RE, Coan AD, Herndon JE, Patz EF. Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage nonsmall-cell lung carcinoma. J Clin Oncol. 2008;26:1459-1464.
27. Kased N, Erasmus JJ, Komaki R, Cox JD. Prognostic value of posttreatment [18F] fluorodeoxyglucose uptake of primary nonsmall cell lung carcinoma treated with radiation therapy with or without chemotherapy: a brief review. J Thorac Oncol. 2008;3:534-538.
28. Tanvetyanon T, Eikman EA, Sommers E, Robinson L, Boulware D, Bepler G. Computed tomography response, but not positron emission tomography scan response, predicts survival after neoadjuvant chemotherapy for resectable nonsmall-cell lung cancer. J Clin Oncol. 2008;26:4610-4616.
29. Marom EM, Aloia TA, Moore MB, et al. Correlation of FDG-PET imaging with Glut-1 and Glut-3 expression in early-stage nonsmall cell lung cancer. Lung Cancer. 2001;33:99-107.
30. Oremek GM, Sauer-Eppel H, Bruzdziak TH. Value of tumour and inflammatory markers in lung cancer. Anticancer Res. 2007;27:1911-1915. (Pubitemid 46954697)
31. Petersen RP, Campa MJ, Sperlazza J, et al. Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer. 2006;107:2866-2872.
32. Maschauer S, Prante O, Hoffmann M, Deichen JT, Kuwert T. Characterization of 18F-FDG uptake in human endothelial cells in vitro. J Nucl Med. 2004;45:455-460.
33. Brown RS, Leung JY, Fisher SJ, Frey KA, Ethier SP, Wahl RL. Intratumoral distribution of tritiated fluorodeoxyglucose in breast carcinoma: I. Are inflammatory cells important? J Nucl Med. 1995;36:1854-1861.
34. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
35. Birchard KR, Hoang JK, Herndon JE, Patz EF. Early changes in tumor size in patients treated for advanced stage nonsmall cell lung cancer do not correlate with survival. Cancer. 2009;115:581-586.
36. Nakamoto Y, Osman M, Cohade C, et al. PET/CT: comparison of quantitative tracer uptake between germanium and CT transmission attenuation-corrected images. J Nucl Med. 2002;43:1137-1143.
37. Souvatzoglou M, Ziegler SI, Martinez MJ, et al. Standardised uptake values from PET/CT images: comparison with conventional attenuation-corrected PET. Eur J Nucl Med Mol Imaging. 2007;34:405-412.
38. Erdi YE, Nehmeh SA, Pan T, et al. The CT motion quantitation of lung lesions and its impact on PET-measured SUVs. J Nucl Med. 2004;45:1287-1292.